Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Key Highlights
- ➤Executive Order 14437 establishes White House Women’s Health Task Force.
- ➤NIH directed to establish a Women’s Health Division.
- ➤DARE to PLAY Sildenafil Cream prescription dispensing anticipated this quarter.
- ➤Daré discussed commercial strategy and clinical pipeline advancements.
Expert Statements
Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience
“the importance of translating increased recognition of women’s health needs into meaningful solutions for women”
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women’s health
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in a Virtual Investor “What This Means” segment discussing the October 19, 2026 Executive Order aimed at strengthening research, prevention, diagnosis, treatment and care for women and girls across every stage of life. Executive Order 14437 established a White House Women’s Health Task Force and directed the U.S. Department of Health and Human Services and the National Institutes of Health (NIH) to establish a Women’s Health Division within NIH.
Get started
Create a free account to read the full story.